U.S. Markets closed

Alimera Sciences announces first patient treated with Iluvien

Alimera Sciences announced that Iluvien, the first sustained release pharmaceutical product for the treatment of chronic diabetic macular edema, or DME, is now commercially available in Germany. In addition, Albert J. Augustin, M.D., professor and chairman of the Department of Ophthalmology, Klinikum Karlsruhe, Karlsruhe, Germany, has treated the world's first patient with the implant injection since the product became commercially available. The patient, a 67-year-old man, was diagnosed with diabetes more than 20 years ago.